BRPI0814105A2 - Métodos e composições para o tratamento de hipertensão pulmonar e doenças e distúrbios relacionados - Google Patents
Métodos e composições para o tratamento de hipertensão pulmonar e doenças e distúrbios relacionadosInfo
- Publication number
- BRPI0814105A2 BRPI0814105A2 BRPI0814105-3A2A BRPI0814105A BRPI0814105A2 BR PI0814105 A2 BRPI0814105 A2 BR PI0814105A2 BR PI0814105 A BRPI0814105 A BR PI0814105A BR PI0814105 A2 BRPI0814105 A2 BR PI0814105A2
- Authority
- BR
- Brazil
- Prior art keywords
- disorders
- compositions
- treatment
- methods
- related diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5578—Eicosanoids, e.g. leukotrienes or prostaglandins having a pentalene ring system, e.g. carbacyclin, iloprost
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
- A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94904007P | 2007-07-11 | 2007-07-11 | |
| PCT/US2008/069471 WO2009009561A1 (en) | 2007-07-11 | 2008-07-09 | Methods and compositions for treating pulmonary hypertension and related diseases and disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0814105A2 true BRPI0814105A2 (pt) | 2015-02-03 |
Family
ID=39730871
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0814105-3A2A BRPI0814105A2 (pt) | 2007-07-11 | 2008-07-09 | Métodos e composições para o tratamento de hipertensão pulmonar e doenças e distúrbios relacionados |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US7875622B2 (pt) |
| EP (1) | EP2170397A1 (pt) |
| JP (1) | JP2010533196A (pt) |
| KR (1) | KR20100046189A (pt) |
| CN (1) | CN101815534A (pt) |
| AU (1) | AU2008275179B2 (pt) |
| BR (1) | BRPI0814105A2 (pt) |
| CA (1) | CA2693400A1 (pt) |
| EA (1) | EA201070127A1 (pt) |
| WO (1) | WO2009009561A1 (pt) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103265495B (zh) | 2005-12-29 | 2016-11-16 | 莱西肯医药有限公司 | 多环氨基酸衍生物及其使用方法 |
| CA2691003A1 (en) * | 2007-06-26 | 2008-12-31 | Lexicon Pharmaceuticals, Inc. | Methods of treating serotonin-mediated diseases and disorders |
| US8093291B2 (en) * | 2007-06-26 | 2012-01-10 | Lexicon Pharmaceuticals, Inc. | Methods of using and compositions comprising tryptophan hydroxylase inhibitors |
| WO2009009561A1 (en) | 2007-07-11 | 2009-01-15 | Lexicon Pharmaceuticals, Inc. | Methods and compositions for treating pulmonary hypertension and related diseases and disorders |
| TW200932729A (en) * | 2007-10-08 | 2009-08-01 | Lexicon Pharmaceuticals Inc | Solid forms of (S)-2-amino-3-(4-(2-amino-6-((R)-2,2,2-trifluoro-1-(3'-methoxybiphenyl-4-yl)ethoxy)pyrimidin-4-yl)phenyl)propanoic acid and methods of their use |
| MX2010010799A (es) * | 2008-03-31 | 2011-03-25 | Univ Columbia | Metodo de diagnostico, prevencion y tratamiento de las enfermedades de la masa osea. |
| US8815883B2 (en) | 2009-11-02 | 2014-08-26 | The Trustees Of Columbia Unviersity In The City Of New York | Compounds and methods for inhibiting serotonin synthesis |
| TWI513694B (zh) | 2010-05-11 | 2015-12-21 | Amgen Inc | 抑制間變性淋巴瘤激酶的嘧啶化合物 |
| EP2582666B1 (en) | 2010-06-16 | 2014-08-13 | Purdue Pharma L.P. | Aryl substituted indoles and their use as blockers of sodium channels |
| WO2013148978A1 (en) | 2012-03-30 | 2013-10-03 | Lexicon Pharmaceuticals, Inc. | Methods and compositions for the treatment of necrotizing enterocolitis |
| ES2805367T3 (es) | 2013-01-11 | 2021-02-11 | Corsair Pharma Inc | Profármacos de treprostinil |
| US9505737B2 (en) | 2013-01-11 | 2016-11-29 | Corsair Pharma, Inc. | Treprostinil derivative compounds and methods of using same |
| UA119247C2 (uk) | 2013-09-06 | 2019-05-27 | РОЙВЕНТ САЙЕНСИЗ ҐмбГ | Спіроциклічні сполуки як інгібітори триптофангідроксилази |
| KR102137214B1 (ko) * | 2013-12-17 | 2020-07-23 | 스텔라파머 가부시키가이샤 | 2-플루오로-4-보로노-l-페닐알라닌의 제조 방법 및 2-플루오로-4-보로노-l-페닐알라닌의 전구체 |
| WO2016010538A1 (en) | 2014-07-16 | 2016-01-21 | Corsair Pharma, Inc. | Treprostinil derivative compounds and methods of using same |
| US9611201B2 (en) | 2015-03-05 | 2017-04-04 | Karos Pharmaceuticals, Inc. | Processes for preparing (R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanol and 1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanone |
| US9643911B2 (en) | 2015-06-17 | 2017-05-09 | Corsair Pharma, Inc. | Treprostinil derivatives and compositions and uses thereof |
| US9394227B1 (en) | 2015-06-17 | 2016-07-19 | Corsair Pharma, Inc. | Treprostinil derivatives and compositions and uses thereof |
| WO2018060949A1 (en) | 2016-09-30 | 2018-04-05 | Roivant Sciences Gmbh | Tryptophan hydroxylase inhibitors for use in the treatment of liver diseases |
| EP3674303B1 (en) * | 2017-08-24 | 2022-07-20 | Gwangju Institute of Science and Technology | Novel tryptophan hydroxylase inhibitor and pharmaceutical composition including same |
| US11413287B2 (en) | 2018-11-16 | 2022-08-16 | Altavant Sciences Gmbh | Method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension |
| WO2020157577A1 (en) | 2019-01-30 | 2020-08-06 | Altavant Sciences Gmbh | A dosage regime and method for treating pulmonary arterial hypertension with rodatristat ethyl |
| KR20210139293A (ko) | 2019-03-15 | 2021-11-22 | 알타반트 사이언시스 게엠베하 | 폐동맥 고혈압 및 연관 폐동맥 고혈압 치료방법 및 매일 투여 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4156734A (en) | 1976-02-13 | 1979-05-29 | Merck & Co., Inc. | Antihypertensive compositions containing an aryl-substituted alanine azo and an arylhydrazino-propionic acid |
| WO1991001724A1 (en) | 1989-07-27 | 1991-02-21 | G.D. Searle & Co. | Renal-selective prodrugs for the treatment of hypertension |
| JP2001517246A (ja) | 1997-06-23 | 2001-10-02 | 田辺製薬株式会社 | α▲下４▼β▲下１▼媒介細胞接着の阻止剤 |
| MY153569A (en) | 1998-01-20 | 2015-02-27 | Mitsubishi Tanabe Pharma Corp | Inhibitors of ?4 mediated cell adhesion |
| CA2385882C (en) | 1999-09-24 | 2009-11-24 | Genentech, Inc. | Tyrosine derivatives |
| TW200400821A (en) * | 1999-11-02 | 2004-01-16 | Pfizer | Pharmaceutical composition (II) useful for treating or preventing pulmonary hypertension in a patient |
| WO2004017993A1 (en) | 2002-08-12 | 2004-03-04 | Actelion Pharmaceuticals Ltd | Combination of prostacyclin or prostacyclin analogues and endothelin receptor antagonists for the treatment of pulmonary arterial hypertension |
| US20060154936A1 (en) * | 2002-10-25 | 2006-07-13 | Lasky Joseph A | Use of n-'5-'4-(4-methylpiperaziomethyl)-benzoylamido!-2-methylphenyl!-4-(3-pyridyl)2-pyridine-amine for the treatment of pulmonary hypertension |
| AU2003297431A1 (en) | 2002-12-20 | 2004-07-22 | Pharmacia Corporation | Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds |
| US6794401B2 (en) | 2003-01-17 | 2004-09-21 | Bexel Pharmaceuticals, Inc. | Amino acid phenoxy ethers |
| JPWO2005044780A1 (ja) | 2003-11-10 | 2007-05-17 | 杏林製薬株式会社 | アミノカルボン酸誘導体とその付加塩及びｓ１ｐ受容体調節剤 |
| EP1735000A2 (en) | 2004-04-16 | 2006-12-27 | Genentech, Inc. | Method for augmenting b cell depletion |
| US7855291B2 (en) | 2005-12-29 | 2010-12-21 | Lexicon Pharmaceuticals, Inc. | Process for the preparation of substituted phenylalanines |
| CN103265495B (zh) | 2005-12-29 | 2016-11-16 | 莱西肯医药有限公司 | 多环氨基酸衍生物及其使用方法 |
| WO2008073928A1 (en) * | 2006-12-12 | 2008-06-19 | Gilead Colorado, Inc. | Composition for treating a pulmonary hypertension |
| UA99270C2 (en) | 2006-12-12 | 2012-08-10 | Лексикон Фармасьютикалз, Инк. | 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use |
| CA2691003A1 (en) | 2007-06-26 | 2008-12-31 | Lexicon Pharmaceuticals, Inc. | Methods of treating serotonin-mediated diseases and disorders |
| WO2009009561A1 (en) | 2007-07-11 | 2009-01-15 | Lexicon Pharmaceuticals, Inc. | Methods and compositions for treating pulmonary hypertension and related diseases and disorders |
-
2008
- 2008-07-09 WO PCT/US2008/069471 patent/WO2009009561A1/en active Application Filing
- 2008-07-09 EP EP08826306A patent/EP2170397A1/en not_active Withdrawn
- 2008-07-09 EA EA201070127A patent/EA201070127A1/ru unknown
- 2008-07-09 KR KR1020107002983A patent/KR20100046189A/ko not_active Application Discontinuation
- 2008-07-09 CN CN200880024101A patent/CN101815534A/zh active Pending
- 2008-07-09 AU AU2008275179A patent/AU2008275179B2/en not_active Ceased
- 2008-07-09 CA CA2693400A patent/CA2693400A1/en not_active Abandoned
- 2008-07-09 US US12/169,815 patent/US7875622B2/en active Active
- 2008-07-09 JP JP2010516210A patent/JP2010533196A/ja active Pending
- 2008-07-09 BR BRPI0814105-3A2A patent/BRPI0814105A2/pt not_active Application Discontinuation
-
2011
- 2011-01-14 US US13/006,592 patent/US8410121B2/en active Active
-
2013
- 2013-03-18 US US13/845,533 patent/US20130274261A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US8410121B2 (en) | 2013-04-02 |
| US20090054308A1 (en) | 2009-02-26 |
| CA2693400A1 (en) | 2009-01-15 |
| JP2010533196A (ja) | 2010-10-21 |
| CN101815534A (zh) | 2010-08-25 |
| EP2170397A1 (en) | 2010-04-07 |
| US20130274261A1 (en) | 2013-10-17 |
| AU2008275179B2 (en) | 2013-09-12 |
| EA201070127A1 (ru) | 2010-08-30 |
| US20110112094A1 (en) | 2011-05-12 |
| AU2008275179A1 (en) | 2009-01-15 |
| WO2009009561A1 (en) | 2009-01-15 |
| KR20100046189A (ko) | 2010-05-06 |
| US7875622B2 (en) | 2011-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0814105A2 (pt) | Métodos e composições para o tratamento de hipertensão pulmonar e doenças e distúrbios relacionados | |
| CY2016017I1 (el) | Συνθεση για θεραπεια πνευμονικης υπερτασης | |
| BRPI0918670A2 (pt) | composições e métodos para o tratamento de disordens mediados por ige | |
| BRPI0813725A2 (pt) | Métodos e composições para tratamento de doenças | |
| SMT201600080B (it) | Inibitori di chinasi janus per il trattamento di occhio secco e altre malattie oculari | |
| BRPI0921237A2 (pt) | métodos e composições para o tratamento de distúrbios associados ao complemento | |
| BRPI0916862A2 (pt) | compostos úteis para o tratamento de doenças degenerativas e inflamatórias | |
| BRPI0919920A2 (pt) | compostos para tratamento de doenças e desordens oftálmicas | |
| BRPI0911757A2 (pt) | composiÇÕes e mÉtodos para tratar distérbios digestivos. | |
| BRPI0908292A2 (pt) | "métodos e composições para administração oral de exenatida" | |
| IL202611A0 (en) | Methods of treating serotonin-mediated diseases and disorders | |
| ZA201000991B (en) | Pharmaceutical compositions and methods of treating dry eye disorders | |
| BRPI0810561A2 (pt) | métodos e composições para tratar e monitorar tratamento de desordens associadas à il-13. | |
| BRPI0817271A2 (pt) | Método de tratamento da doença de parkinson e outros distúrbios relacionados | |
| DK3456707T3 (da) | 4-(p-quinonyl)-2-hydroxybutanamidderivater til behandling af mitokondriesygdomme | |
| DK2207550T3 (da) | Tetrahydroquinolinderivater til behandling af post-traumatiske stress-lidelser | |
| HK1217100A1 (zh) | 檢測和治療阿爾茨海默病和相關疾病的化合物和組合物 | |
| HK1146894A1 (en) | Compositions and methods for treating diseases of the nail | |
| BRPI0908026A2 (pt) | Métodos para o tratamento de doenças do intestino | |
| BRPI0819241A2 (pt) | Compostos derivados de amina para o tratamento de distúrbios e doenças oftálmicas | |
| BRPI0907077A2 (pt) | métodos e composições para administração oral de proteínas | |
| PL2379088T3 (pl) | Leczenie płuca oraz chorób i zaburzeń płucnych | |
| BRPI1014759A2 (pt) | composto útil para o tratamento de doenças degenerativas e inflamatórias | |
| BRPI0822349A2 (pt) | composições e métodos para tratar doenças lisossômicas | |
| BRPI0812755A2 (pt) | Compostos de derivados de fenil alquinila para tratar doenças, e desordens oftálmicas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |